MedTrace Logo

Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

NCT00750919 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2021-02-02

Study results available
· View outcomes & findings →

Summary

This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).

Conditions

  • Sleep Initiation and Maintenance Disorders
  • Mental Disorders
  • Dyssomnias
  • Sleep Disorders
  • Sleep Disorders, Intrinsic

Interventions

DRUG

esmirtazapine

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-07
Primary Completion
2010-03-10
Completion
2010-03-10

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750919 on ClinicalTrials.gov